Dual-engineered extracellular vesicles enabling endothelial targeting and EphrinB2 delivery for pulp revascularization Authors: Anqi Liu, Mengying Li, Peiyu Tang, Weiwen Ge, Zhengliang Han, Yige Dai, Lei Zhang, Changyong Yuan, Lei Qi Published: 2026 ABSTRACT Dental pulp pathologies impair quality of life and systemic health. Obstacles to revascularization remain a key challenge in regenerating dental pulp tissue. To address these challenges, dual-engineered extracellular vesicles (EVs) were developed, incorporating EphrinB2 as a pro-regenerative payload alongside the DNA aptamer Apt02 for endothelial-targeting specificity. This study identified 1 µg/mL as the optimal concentration for fabricating EphrinB2-loaded extracellular vesicles (B2-EVs). At this concentration, B2-EVs significantly enhanced the proliferation, migration, and capillary morphogenesis of HUVECs. Subsequent integration of the endothelial-targeting Apt02 yielded Apt-B2-EVs, which demonstrated superior affinity for HUVECs and amplified pro-angiogenic capacity. Mechanistic analyses confirmed that Apt-B2-EVs promote angiogenesis via the EphrinB2/EphB4-dependent Akt/ERK signaling cascade. These vesicles were further encapsulated within methacrylated gelatin (GelMA) hydrogel, exhibiting sustained release kinetics and excellent biocompatibility. Implantation of Apt-B2-EVs@GelMA into root canals established pulp organoids, which, upon ectopic transplantation in nude mice, robustly enhanced vascularization. The dual-engineered Apt-B2-EVs present a potent strategy for recruiting endothelial cells and delivering EphrinB2 to enable functional pulp revascularization within root canal niches, laying a translational foundation for next-generation functional pulp regeneration.Graphical Abstract Schematic diagram of the construction of Apt-B2-EVs@GelMA with endothelial cell recruitment and pro-angiogenic functions for enhanced pulp revascularization in vitro and in vivo Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12951-026-04736-0. Introduction In the context of global oral health burdens, dental caries and trauma frequently induce pulp-periapical pathologies [1]. These conditions compromise pulp-dentin integrity by impairing microcirculation and disrupting reparative dentinogenesis, both fundamentally driven by disturbances in the vascular microenvironment [2]. While root canal therapy controls infection, it fails to reconstruct functional vascular networks, thereby compromising dental biomechanics [3]. Conventional revascularization techniques, which rely on apical blood clots, partially achieve root development but often result in sensory loss, calcific metamorphosis, increased fracture risk, and insufficient vascularization [4, 5]. Consequently, novel strategies for pulp revascularization are urgently needed. Functional pulp regeneration critically depends on successful vascular reconstruction, a process orchestrated by key signaling molecules [6–9]. Among them, EphrinB2 has emerged as a pivotal angiogenic ligand that promotes endothelial sprouting and vascular patterning via EphB4 receptor binding [10–13], a role corroborated by our prior work in bone regeneration [14, 15]. However, the translational path of EphrinB2 obstructed by significant barriers, most notably its intrinsic instability as a protein, which leads to rapid degradation and functional loss. This fundamental limitation, alongside challenges in targeted delivery and safety, underscores the urgent need for an advanced delivery platform to harness its full regenerative potential. Extracellular vesicles (EVs) have emerged as promising nanocarriers for pulp revascularization owing to their biocompatibility and innate bioactive cargo [16–18]. Notably, EVs derived from dental pulp stem cells (DPSC-EVs) exhibit superior pro-angiogenic capacity and stability compared to their parent cells [19, 20], making them ideal vehicles for delivering unstable therapeutics like EphrinB2 [21]. Nevertheless, the feasibility and regenerative potential of EphrinB2-loaded EVs (B2-EVs) in pulp revascularization remain unexplored. A key challenge in EV-based therapy is to achieve efficient accumulation at the injury site, as the targeting efficiency of native DPSC-EVs may be insufficient for precise regenerative applications [22–24]. To address this potential limitation, we employed DNA aptamers, as synthetic single-stranded oligonucleotides, which offer high-affinity targeting, low immunogenicity, and programmable stability [25]. Building on our prior success with aptamer-engineered EVs for stem cell recruitment, we posited that conjugating a vascular-targeting aptamer (Apt02) to B2-EVs could confer the necessary homing ability [26, 27]. The vascular-targeting aptamer Apt02 is particularly promising, as it mimics VEGF bioactivity to promote angiogenesis [28–30]. We reasoned that engineering B2-EVs with Apt02 (creating Apt-B2-EVs) would concurrently provide targeted delivery and potent angiogenic stimulation, directly addressing the limitations of native EVs. However, the functional efficacy and targeting specificity of Apt02-engineered B2-EVs (Apt-B2-EVs) for pulp revascularization remain unelucidated, representing a critical knowledge gap with significant therapeutic implications. This study aims to develop a novel dual-functional extracellular vesicle system that integrates the complementary advantages of EphrinB2 and Apt02 to address the regenerative requirements of pulp revascularization. The platform is designed to simultaneously promote angiogenesis through EV-encapsulated EphrinB2 and enable targeted endothelial cell recruitment via surface-conjugated Apt02. We hypothesize that this dual-engineering strategy will demonstrate superior regenerative efficacy compared to single-component approaches. Specifically, the Apt-B2-EVs complex promotes robust angiogenesis by activating the Akt/ERK pathway downstream of EphrinB2/EphB4 bidirectional signaling, which in turn drives endothelial cell migration, proliferation, and stabilization of nascent vasculature. To evaluate this hypothesis, we established a biomimetic pulp-dentin organoid model using dental canals within GelMA hydrogel and assessed the system’s capacity to orchestrate vascular morphogenesis through subcutaneous implantation [31, 32], providing comprehensive mechanistic and functional validation (Scheme 1). Collectively, this work aims to provide a comprehensive and targeted therapeutic strategy to promote pulp revascularization. Scheme 1Schematic diagram of the construction of Apt-B2-EVs@GelMA with endothelial cell recruitment and pro-angiogenic functions for enhanced pulp revascularization in vitro and in vivo Schematic diagram of the construction of Apt-B2-EVs@GelMA with endothelial cell recruitment and pro-angiogenic functions for enhanced pulp revascularization in vitro and in vivo Methods and materials Cell culture and characterization DPSCs were isolated from ten healthy donors (aged 18–25 years) with the following criteria: inclusion - intact and healthy third molars extracted due to impaction; exclusion - teeth with caries, pulpitis, or periapical periodontitis, and donors with systemic diseases, smoking history, or recent use of medications affecting stem cell function. The study protocol was approved by the Institutional Review Board of Affiliated Stomatological Hospital of Xuzhou Medical University (Approval No. 2023-KY-005-01) and was conducted in accordance with the Declaration of Helsinki. After obtaining informed consent, pulp tissues were gently separated from the pulp chambers and minced into small fragments. Tissue dissociation was performed using collagenase type I and dispase solutions (4 mg/mL; Sigma-Aldrich, MO, USA) to obtain single-cell suspensions. The cells were seeded into 6 cm² culture dishes containing α-minimum essential medium (α-MEM; Gibco, Thermo Fisher Scientific, Beijing, China) supplemented with 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, USA) and 100 IU/mL penicillin/streptomycin (Sigma-Aldrich, MO, USA). Prior to experimentation, DPSCs were characterized by flow cytometry (Beckman Coulter, USA) using antibodies against CD34, CD90, CD73, CD105, and CD146 (BioLegend, China). Morphological evaluation of DPSCs at passages P0 and P3 was conducted using an inverted microscope (Zeiss Axio Observer, Oberkochen, Germany). Cells from different donors were pooled at passage 3 to minimize donor-dependent variations, and all subsequent experiments were performed using this pooled cell population. Human umbilical vein endothelial cells (HUVECs) (ScienCell Research Laboratories, San Diego, CA) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) supplemented with 10% FBS. All cells were cultured at 37 °C in a 5% CO2 atmosphere and passaged at 70–80% confluence. Early-passage cells were used for subsequent experiments. Engineered extracellular vesicles fabrication DPSC-EVs were isolated from DPSCs as previously described [20]. In brief, when the cells reached 70–80% confluence, the medium was replaced with EVs-free FBS. After 48 h, culture supernatants were collected and sequentially centrifuged at 800×g for 10 min and 3,000×g for 10 min to remove cellular debris, followed by centrifugation at 10,000×g for 30 min to eliminate microvesicles. The clarified supernatants were then ultracentrifuged at 120,000×g for 70 min at 4 °C. The resulting EVs pellets were resuspended in phosphate-buffered saline (PBS), filtered through 0.2 μm syringe filters, and stored at −80 °C for long-term preservation until subsequent experiments. The protein concentration of EVs was determined using a bicinchoninic acid (BCA) assay kit (CWBioTech, Beijing, China). All functional experiments used EVs normalized to a specific concentration based on this total protein measurement (expressed in µg/mL). B2-EVs were constructed by sonicating a mixture of DPSC-EVs and recombinant EphrinB2 protein in PBS using a Qsonica Q700 sonicator (Fisher Scientific, USA). The mixture underwent six cycles of 4-s pulses with 2-s pauses at 500 V, 2 kHz, and 20% power, with ice cooling for 2 min between cycles [33]. To confer endothelial cell-targeting capabilities, EVs and B2-EVs were functionalized with Apt02. Cy5-labeled Apt02, modified with a 5’-aldehyde group (Sangon Biotech), was conjugated to the amino groups of B2-EVs via Schiff base reaction by incubating 200 nM Apt02 with 1 mg/mL EVs or B2-EVs in PBS under continuous rotation at 4 °C overnight to generate Apt-EVs and Apt-B2-EVs. Unbound Apt02 was removed through three centrifugation washes (100,000×g, 70 min) using 100 kDa ultrafiltration tubes. Scrambled-sequence oligonucleotides (sequences in Supplementary Table S1) were conjugated to B2-EVs under identical conditions as negative controls. Characterization of EVs and B2-EVs EVs and B2-EVs were characterized using transmission electron microscopy (TEM; JEOL, Japan), nanoparticle tracking analysis (NTA; NanoSight NS300; Malvern, UK), and western blotting (WB) to assess morphology, size distribution, and protein biomarkers, respectively. For morphological analysis, samples were adsorbed onto carbon-coated copper grids for 5 min, negatively stained with 2% phosphotungstic acid (pH 7.0) for 1 min, and imaged at 80 kV. Particle size distribution was analyzed by NTA using three 60-s videos per sample at camera level 14. For biomarker characterization, proteins were extracted with RIPA buffer (Thermo Fisher, USA), separated by 10% SDS-PAGE, and transferred to PVDF membranes (Millipore, USA). Western blot analysis was performed to simultaneously characterize EV markers and assess purity. Membranes were probed with anti-CD9, anti-CD63, and anti-CD81 antibodies to confirm EV identity, and with anti-GM130 and anti-Calnexin antibodies to exclude cellular contamination, respectively. All incubations used primary antibodies overnight at 4 °C, followed by HRP-conjugated secondary antibodies and ECL detection (Bio-Rad, USA). Enzyme-linked immunosorbent assay (ELISA) After engineering the EVs, free EphrinB2 concentrations in B2-EVs-containing supernatants were quantified using a Human EphrinB2 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN). Supernatants were centrifuged to remove particulate debris. Microplate strips were removed from the frame, and 50 µl of Assay Diluent RD1W was added to each well. Subsequently, 200 µl of diluted EphrinB2 standards, controls, or samples were added to designated wells. After a 60-min incubation at room temperature, the wells were washed, followed by the addition of 200 µl of EphrinB2 conjugate. Plates were incubated in the dark for 15 min before terminating the reactions with 50 µl of stop solution. Optical density was measured at 450 nm using a microplate reader. The loading amount of EphrinB2 was determined by a mass balance approach: Loaded EphrinB2 (µg) = Total Input EphrinB2 (µg) - Free EphrinB2 in Supernatant (µg); The loading efficiency was calculated as: Loading Efficiency (%) = (Loaded EphrinB2/Total Input EphrinB2) × 100%. where free EphrinB2 concentration was measured by ELISA. The calculated loaded amount was used for normalization in all functional experiments. Verification of Apt02 affinity To validate aptamer-EVs conjugation, B2-EVs were incubated with 200 nM Cy5-Apt02 (with or without aldehyde modification) for 60 min at 37 °C under rotation. Free aptamers were removed by centrifugation at 500×g for 5 min in PBS. The EVs-aptamer complexes were resuspended in filtered PBS and analyzed using a FACSCanto II flow cytometer (BD Biosciences; 640-nm laser, 670/14-nm filter). It is important to note that the flow cytometry analysis specifically detected the Cy5 signal from the bound aptamer rather than the EVs themselves. Fluorescence-positive populations were quantified using FlowJo v10.0, with unstained EVs serving as negative controls to define gating thresholds. The conjugation efficiency was quantitatively determined by comparing the Cy5 fluorescence intensity of the purified Apt-B2-EVs complex to that of the initial free Cy5-Apt02 solution using a fluorescence microplate reader. The conjugation efficiency was calculated as: (Fluorescence intensity of Apt-B2-EVs/Fluorescence intensity of initial Cy5-Apt02) × 100%. Verification of Apt02 binding specificity in inflammation To evaluate the cellular uptake and targeting specificity of Apt-B2-EVs under inflammation, HUVECs were seeded onto confocal dishes. Cells were treated with 1 µg/mL LPS for 6 h to induce inflammation, while controls received normal medium. Both groups were then incubated with dual-labeled Apt-B2-EVs (PKH67-green for EVs, Cy5-red for aptamer) for 2–4 h at 37 °C. After fixation and DAPI staining, fluorescence was visualized by confocal microscopy. EVs labeling and cellular internalization assay EVs were fluorescently labeled with PKH67 (Sigma-Aldrich, USA) according to the manufacturer’s guidelines. Briefly, EVs were incubated with 2 µM PKH67 for 5 min at 37 °C, followed by ultracentrifugation at 170,000×g for 30 min and two PBS washes (170,000×g, 30 min) to remove unbound dye. Labeled EVs (EVs, B2-EVs, or Apt-B2-EVs) were resuspended in PBS for subsequent experiments. To validate Apt02-mediated targeting specificity, Apt-B2-EVs were dual-labeled with PKH67 (EVs membrane) and Cy5 (Apt02), while B2-EVs conjugated with scrambled-sequence Apt02 served as negative controls. For internalization studies, target cells, including HUVECs, bone marrow mesenchymal stem cells (BMSCs), DPSCs, human dental pulp fibroblasts (HDPFs), and odontoblast-like cells (OLCs). These cells were seeded in 24-well plates containing glass slides and pre-cultured in DMEM with 10% FBS for 6 h. Cells were treated with PKH67-labeled EVs (1 µg/105 cells) at 37 °C for 4 h. Following incubation, cells were washed three times with ice-cold PBS to terminate uptake, fixed with 4% paraformaldehyde (15–30 min depending on cell type), and permeabilized with 0.1% Triton X-100 (15 min). For HUVECs, cytoskeletal staining was performed using TRITC-phalloidin (Solarbio, China; 30 min), while nuclei of all cell types were counterstained with DAPI (Invitrogen, USA; 10 min) [26]. Cell proliferation assay To investigate the dose- and time-dependent effects of EVs on HUVEC proliferation using the CCK-8 assay, we first established the working concentration of unmodified EVs based on total protein content (µg/mL). HUVECs were seeded at 3,000 cells/well in 96-well plates and allowed to adhere. Cells were then treated with increasing concentrations of unmodified EVs (0, 20, 40, 80, and 160 µg/mL) for 48 h, with peripheral wells filled with PBS to minimize evaporation. Following treatment, the medium was replaced with 100 µl of fresh medium containing 10% CCK-8 reagent (Dojindo, Japan). After 1 h of incubation at 37 °C, absorbance was measured at 450 nm using a Spectramax M5 microplate reader (Molecular Devices, USA). Subsequently, to optimize EphrinB2 concentration parameters, engineered B2-EVs were prepared via sonication-assisted incubation with varying EphrinB2 concentrations (0.5, 1, 2, and 4 µg/mL) [15], designated as 0.5-B2-EVs, 1-B2-EVs, 2-B2-EVs, and 4-B2-EVs, respectively, according to the methodology detailed in the "Engineered extracellular vesicles fabrication" section. These B2-EVs formulations were applied to cells for 24, 48, and 72 h, followed by the same CCK-8 processing and measurement procedures. Finally, to determine the optimal concentration of B2-EVs, cells were treated with serially diluted B2-EVs (20–160 µg/mL) for 48 h. All experiments were performed in triplicate, and data were analyzed to establish dose-dependent proliferation kinetics across time points. Viability and cytotoxicity assessment In addition to the CCK-8 assay, a Live/Dead assay was performed to directly visualize cell viability and potential cytotoxic effects. HUVECs were treated with EVs (20–160 µg/mL) for 48 h. Cells were then stained using a calcein-AM (2 µM) and propidium iodide (PI, 4 µM) mixture (Beyotime, China) according to the manufacturer’s protocol. After 30 min of incubation at 37 °C, images were captured using a fluorescence microscope (Nikon, Japan). Viable cells (calcein-AM positive, green fluorescence) and dead cells (PI positive, red fluorescence) were quantified from three random fields per well. Wound-healing assay HUVECs were seeded in 6-well plates at a density of 2 × 105 cells/well and cultured to confluency. A linear wound was created using a sterile 200 µl pipette tip. After PBS washing to remove debris, cells were treated with EphrinB2 solution alone, EVs, B2-EVs, Apt-EVs or Apt-B2-EVs in DMEM supplemented with 10% FBS. Wound areas were imaged at 0, 24, and 48 h using an inverted microscope (Olympus, Japan) and quantified with ImageJ. Wound closure percentage was calculated using the formula: [(Initial area – Residual area)/Initial area] ×100%. Transwell assay The migration capacity of HUVECs was evaluated using 8 μm-pore Transwell inserts (Corning, NY, USA). Briefly, 2 × 104 cells suspended in serum-free medium were seeded into the upper chambers, while 700 µl of medium containing EphrinB2 solution alone, EVs, B2-EVs, Apt-EVs or Apt-B2-EVs with 10% FBS was added to the lower chambers. After 24 h of incubation, non-migrated cells were removed from the upper membrane surface. Migrated cells on the lower surface were fixed with 4% paraformaldehyde for 15 min, stained with 0.5% crystal violet for 10 min, and quantified by counting five random fields per insert under an optical microscope (Nikon, Japan). Cell counts were analyzed using ImageJ. Tube formation assay The angiogenic potential of engineered EVs was evaluated using a Matrigel-based tube formation assay. HUVECs were seeded at 2.0 × 104 cells/well in 96-well plates pre-coated with 50 µl of Matrigel (BD Biosciences, USA), applied using pre-chilled pipette tips at 4°C. After polymerization at 37 °C for 30 min, cells were treated with 100 µl of medium containing PBS, EphrinB2 solution, EVs, B2-EVs, Apt-EVs or Apt-B2-EVs. Following a 4 h incubation, Calcein-AM (1:1000; Abcam) was applied for 30 min at 37 °C to fluorescently label living cells. Tube networks were imaged using an inverted fluorescence microscope (Nikon, Japan). Total tube length and the number of branch points per field were quantified from five random fields per well using ImageJ. All experiments were conducted in triplicate. Western blot HUVECs were treated with EphrinB2 solution, EVs, B2-EVs, Apt-EVs, Apt-B2-EVs, Apt-B2-EVs+Akti, Apt-B2-EVs+ERKi, Apt-B2-EVs + NT siRNA or Apt-B2-EVs+EphB4 siRNA for 48 h in 6-well plates. After three washes with ice-cold PBS, proteins were extracted using RIPA buffer supplemented with protease and phosphatase inhibitors. Lysates were homogenized by ultrasonication, centrifuged at 12,000×g, and protein concentrations were quantified using a BCA assay. Proteins were separated by 10% SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% bovine serum albumin (BSA) for 30 min at room temperature, then incubated overnight at 4 °C with primary antibodies (Supplementary Table S2), followed by incubation with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using an ECL kit and normalized to β-actin or GAPDH. All experiments were performed in triplicate. Quantitative real time PCR analysis HUVECs were treated with EphrinB2 solution, EVs, B2-EVs, or Apt-B2-EVs for 48 h in 6-well plates. Following three washes with ice-cold PBS, total RNA was extracted using TRIzol reagent (Invitrogen, USA). For mRNA quantification, cDNA was synthesized from 1 µg of RNA using the PrimeScript RT Master Mix (Takara, Japan). Gene expression was analyzed using TB Green Premix Ex Taq II (Takara), with GAPDH as the reference gene. For miRNA analysis, total RNA underwent poly(A) tailing and reverse transcription using a miRNA 1 st Strand cDNA Synthesis Kit (Sangon Biotech, China), followed by SYBR Green-based qPCR under identical cycling conditions. Relative expression levels were calculated using the 2−ΔΔCT method. Primer sequences are listed in Supplementary Table S3. All experiments were conducted in triplicate. Chemical inhibition of Akt and ERK pathways To evaluate the role of Akt and ERK signaling in Apt-B2-EVs-mediated angiogenesis, HUVECs were serum-starved for 6 h to reduce background signaling. Cells were then pretreated with 10 µM Akt inhibitor (MCE) or 10 µM ERK1/2 inhibitor (TargetMol) for 1 h, while control cells received serum-free medium only. Subsequently, Apt-B2-EVs were added to the culture medium and incubated for 30 min. After stimulation, cells were either lysed for Western blot analysis or harvested for functional assays. For Western blotting, cells were washed with cold PBS and lysed in RIPA buffer containing protease and phosphatase inhibitors. For functional assays (migration, invasion, tube formation), cells were trypsinized, washed, and resuspended in serum-free medium before seeding. siRNA-mediated gene silencing of EphB4 For siRNA-mediated gene silencing, HUVECs were seeded at 30–50% confluence and transfected 24 h later at approximately 60–70% confluence. EphB4 siRNA or negative control (NT) siRNA (50 nM) was diluted in DMEM and mixed with Lipofectamine 3000 transfection reagent. The mixture was incubated for 15 min at room temperature to form siRNA-transfection complexes, which were then added dropwise to the cells. After 4 h, the medium was replaced with fresh complete medium. At 48 h post-transfection, cells were serum-starved and then stimulated with Apt-B2-EVs for the indicated times prior to subsequent analyses. For Western blotting, cells were harvested for protein collection. For functional assays (migration, invasion, tube formation), cells were trypsinized, washed, and resuspended in serum-free medium before seeding. Preparation of Apt-B2-EVs@GelMA tooth section scaffolds Lyophilized GelMA was dissolved in DMEM containing 0.3% (w/v) lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) photoinitiator under light-protected conditions and heated at 65 °C for 30 min to prepare a 5% (w/v) precursor solution. After sterilization through a 0.22 μm filter, EphrinB2 solution, EVs, B2-EVs, or Apt-B2-EVs were mixed with the GelMA precursor, with PBS serving as a control. GelMA precursor solutions were photocrossloaded in 24-well plates using a 405 nm UV light source (9.16 W/cm² at 20 mm working distance) for 25 s at room temperature to form stable hydrogels. HUVECs (1 × 104 cells/well) were encapsulated within the EVs-loaded GelMA hydrogels and cultured for 48 h in complete DMEM. Cell viability was evaluated by incubating hydrogels with Calcein-AM (2 µM) and PI (4.5 µM) at 37 °C for 30 min, followed by fluorescence imaging (Olympus IX73). To assess sustained EVs release, EVs@GelMA constructs (0.5 mL) were immersed in 10 mL PBS, and supernatants were collected at specified intervals for BCA protein quantification [31]. Single-rooted teeth from healthy donors (15–30 years) were sectioned into 6–10 mm root fragments (2–3 mm orifice width) using sterilized burs. Teeth with any pathology were excluded. Pulpal spaces were sequentially enlarged with Gates Glidden drills (#1–2) and burs. Specimens were irrigated alternately with 5.25% NaOCl (10 min) and EDTA solutions (5%, 10%, 17%; 5 min each), followed by PBS rinsing. All specimens were then sterilized by autoclaving (121℃, 15 psi, 20 min) and underwent sterility confirmation through 5-day incubation in DMEM before being embedded in GelMA hydrogel. White mineral trioxide aggregate (MTA; ProRoot) was placed at one terminus to mimic apexification while maintaining coronal patency [32]. Following standard protocols, HUVEC-laden GelMA containing the test formulations was injected into tooth fragments, photocrosslinked, and prepared for animal implantation. Animal surgical procedures All animal procedures were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Affiliated Stomatological Hospital of Xuzhou Medical University (Approval No. 2023-KY-005-01). Anesthetized nude mice (1% pentobarbital sodium, 50 mg/kg, intraperitoneally) underwent dorsal subcutaneous implantation under aseptic conditions. A 10 mm incision was made to create a blunt-dissected pocket into which scaffold-root complexes (5 × 5 × 2 mm) were inserted. Hemostasis was confirmed before layered wound closure using 4 − 0 Vicryl and 5 − 0 nylon sutures. Five experimental groups were established: (1) PBS@GelMA; (2) B2@GelMA; (3) EVs@GelMA; (4) B2-EVs@GelMA; (5) Apt-B2-EVs@GelMA (n = 5/group). Postoperatively, mice received meloxicam (2 mg/kg for 3 days), warm saline, and nutritional supplementation including sunflower seeds. At the 8-week endpoint, implants were harvested with 2 mm tissue margins under terminal anesthesia. Specimens were either cryopreserved or fixed in 10% EDTA (pH 7.0, 8 weeks) for decalcification, paraffin embedding, and histological analysis of neovascularization. Animal assignment to experimental groups was performed randomly using a computer-generated randomization sequence. All histological evaluations were conducted by two independent investigators blinded to group allocation throughout the data collection and analysis process. Hematoxylin and eosin staining (H&E) Tissue sections were stained with H&E following standard protocols. Briefly, paraffin-embedded sections were deparaffinized at 65 °C for 1 h, followed by two sequential immersions in xylene (15 min each). Rehydration was performed through a graded ethanol series (100%−70%), and nuclei were stained with hematoxylin for 2 min. Sections were differentiated in 1% hydrochloric acid–ethanol, blued in 0.2% ammonia water, and counterstained with eosin for 2 min. After dehydration through graded ethanol and clearing in xylene, sections were mounted with neutral resin. Immunofluorescence For VEGF detection, tissue sections were deparaffinized, rehydrated, and subjected to antigen retrieval in citrate buffer (pH 6.0) at 95 °C for 20 min. After cooling and PBS washing, sections were permeabilized with 0.5% Triton X-100 for 15 min. Non-specific binding was blocked with 5% BSA for 20 min at room temperature. Sections were incubated overnight at 4 °C with an anti-VEGF antibody, followed by an Alexa Fluor 488-conjugated secondary antibody (1:500, 1 h, room temperature). Nuclei were counterstained with DAPI. Fluorescence images were acquired using an FV10i microscope (Olympus, Japan) and analyzed with ImageJ. VEGF-positive areas were quantified in five random fields by threshold-based grayscale analysis. Statistical analysis Data are presented as mean ± SD from three independent biological replicates (n = 3) using separate cell cultures, with technical replicates employed within each experiment. Intergroup comparisons were analyzed using two-tailed Student’s t-tests, while multigroup comparisons were assessed by one-way ANOVA. Statistical significance was defined as p < 0.05. All analyses and graphical presentations were performed using GraphPad Prism (GraphPad Software, version 9.0). Results and discussion Isolation, characterization, and cellular uptake of B2-EVs DPSCs, pivotal seed cells for pulp regeneration, modulate angiogenesis through paracrine signaling or EVs-mediated processes [18]. In our study, spindle-shaped cells migrated from explants and adhered to the culture surfaces within 7 days. P3 DPSCs exhibited strong proliferation (Fig. S1A) and expressed characteristic mesenchymal stem cell (MSC) markers CD105 (99.86%), CD90 (99.94%), and CD73 (99.84%), with minimal CD34 expression (0.27%), confirming their stem cell identity (Fig. S1B). These results demonstrate that the DPSCs were successfully isolated, showing robust proliferative capacity and a typical MSC phenotype. In recent years, DPSC-derived EVs have demonstrated remarkable therapeutic potential across multiple disciplines, including dentistry, neurology, and immunology [34–36]. However, the clinical application of native EVs is constrained by functional limitations and homogeneous cargo profiles. To address these challenges, engineered EVs modifications have emerged as a promising strategy [37–39]. EphrinB2, a key ligand of the EphB4 receptor, plays a pivotal role in modulating vascular morphogenesis and stem cell signaling pathways [40–43]. Our prior research revealed that recombinant EphrinB2-Fc protein directly stimulates proliferation, migration, and angiogenesis in HUVECs [15]. Meanwhile, lentiviral-mediated EphrinB2 overexpression in periodontal ligament stem cells (PDLSCs) significantly enhanced the expression of osteogenic and odontogenic differentiation markers [14, 44]. Collectively, these findings establish the dual regenerative capacities of EphrinB2 in both vascular and osseous contexts. Motivated by this therapeutic potential, we engineered B2-EVs and validated their regenerative capacity in pulp revascularization. As illustrated in Fig. 1A, B2-EVs were functionalized using an optimized ultrasound-assisted co-incubation protocol, which enabled efficient EphrinB2 loading while preserving vesicle integrity. TEM analysis of EVs and B2-EVs extracted from the DPSC supernatant revealed a diameter of approximately 100 nm, with a characteristic saucer-like or concave hemispherical morphology (Fig. 1B). Western blot analysis of our EV preparations demonstrated positive expression of canonical markers (CD81, CD9, CD63) and a lack of detectable cellular contaminants (GM130, Calnexin), in clear contrast to whole cell lysates, thereby demonstrating their high purity (Fig. 1C). Furthermore, NTA analysis showed that both EVs and B2-EVs maintained consistent mean diameters ranging from 50 to 200 nm (Fig. 1D). CCK-8 assays indicated that EVs stimulated HUVEC proliferation in a dose-dependent manner up to 40 µg/mL, with no further enhancement observed at higher concentrations (80–160 µg/mL) (Fig. 1E). To further validate the biosafety of Apt-B2-EVs at high concentrations, Live/Dead assay results aligned with CCK-8 data, showing predominant green fluorescence and minimal cell death across all tested doses (20–160 µg/mL). Quantitative analysis confirmed > 95% cell viability, supporting the excellent biocompatibility of our engineered EVs (Fig. S2). Building upon these findings, we next evaluated the optimal EphrinB2 conjugation concentration. Significant proliferation was observed at 1 µg/mL EphrinB2, with comparable effects at 2 and 4 µg/mL, while 0.5 µg/mL showed minimal activity (Fig. 1F). Importantly, 40 µg/mL B2-EVs consistently induced maximal proliferation across all tested EphrinB2 concentrations (0.5–2 µg/mL), with no additional benefit at higher levels (Fig. 1G). These results identified 40 µg/mL as the optimal working concentration for functional studies. ELISA results showed that the calculated EphrinB2 loading efficiency for 1-B2-EVs reached 34.39% (±2.24%) (Fig. 1H), confirming the methodological reliability [33]. Fluorescence microscopy demonstrated robust intracellular uptake of both PKH67-labeled EVs and 1-B2-EVs by HUVECs, as indicated by distinct punctate green fluorescent signals distributed throughout the cytoplasm (Fig. 1I). This internalization provides a mechanistic basis for their subsequent modulation of endothelial cell functions. Fig. 1Isolation, characterization, and cellular uptake of B2-EVs. (A) Schematic illustration of B2-EVs construction; (B) Transmission electron microscopy (TEM) images of EVs and B2-EVs, scale bar: 100 nm; (C) Western blot analysis of CD9, CD63, CD81, GM130 and Calnexin in EVs and B2-EVs; (D) Nanoparticle tracking analysis (NTA) of EVs and B2-EVs; (E) Optimization of EVs working concentrations in HUVEC proliferation assays; (F) Determination of optimal EphrinB2 loading concentrations via CCK-8 assays; (G) Functional validation of B2-EVs working concentrations in HUVECs; (H) EphrinB2 loading efficiency quantified by ELISA; (I) Cellular internalization of PKH67-labeled EVs and B2-EVs (green) by HUVECs, with cytoskeletal staining by phalloidin (red) and nuclear counterstaining by DAPI (blue), scale bar: 200 μm. Data represent mean ± SD (n = 3). Significance was calculated by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significance) Isolation, characterization, and cellular uptake of B2-EVs. (A) Schematic illustration of B2-EVs construction; (B) Transmission electron microscopy (TEM) images of EVs and B2-EVs, scale bar: 100 nm; (C) Western blot analysis of CD9, CD63, CD81, GM130 and Calnexin in EVs and B2-EVs; (D) Nanoparticle tracking analysis (NTA) of EVs and B2-EVs; (E) Optimization of EVs working concentrations in HUVEC proliferation assays; (F) Determination of optimal EphrinB2 loading concentrations via CCK-8 assays; (G) Functional validation of B2-EVs working concentrations in HUVECs; (H) EphrinB2 loading efficiency quantified by ELISA; (I) Cellular internalization of PKH67-labeled EVs and B2-EVs (green) by HUVECs, with cytoskeletal staining by phalloidin (red) and nuclear counterstaining by DAPI (blue), scale bar: 200 μm. Data represent mean ± SD (n = 3). Significance was calculated by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significance) B2-EVs promote migration and angiogenesis of HUVECs in vitro Successful dental pulp regeneration critically depends on the efficient re-establishment of a functional vascular network. Neo-angiogenesis is essential, as it not only supplies oxygen and nutrients to the regenerating tissue but also facilitates intercellular communication and waste removal, thereby maintaining the homeostasis of the regenerative microenvironment and enabling functional tissue recovery [45–47]. In this study, we engineered B2-EVs and systematically optimized the loading parameters to maximize therapeutic efficacy. Scratch assay results showed that wound areas were comparable across all groups immediately post-scratch (0 h). Notably, at both 24 and 48 h post-injury, significant enhancement in wound closure was observed in groups treated with either 1-B2-EVs or 2-B2-EVs compared to the control group. Furthermore, the efficacy of the two B2-EVs formulations in promoting endothelial cell migration for wound repair was comparable (Fig. 2A, C). Similarly, Transwell assays showed that both 1-B2-EVs and 2-B2-EVs promoted robust HUVEC transmigration, with significantly more crystal violet-positive cells observed in the lower chamber compared to control groups (Fig. 2B, D). While B2 and EVs alone showed modest pro-migratory effects, B2-EVs demonstrated the highest migratory potency. Fluorescence microscopy analysis revealed that 1-B2-EVs and 2-B2-EVs induced the most robust capillary-like structures (Fig. 2E, F). In contrast, EVs and free B2 alone showed only moderate pro-angiogenic effects, as indicated by branch length and node counts. These results demonstrate that B2-EVs synergistically enhance endothelial tubular morphogenesis, surpassing the individual effects of their components. Functional assays confirmed that the conjugated EphrinB2 retained its bioactivity, demonstrating intact ligand-receptor interactions. Through a comprehensive evaluation of cost-effectiveness and biological potency, we identified 1 µg/mL as the optimal EphrinB2 loading concentration for B2-EVs to maximize proliferative, migratory, and angiogenic responses. Moreover, 1-B2-EVs exhibited superior efficacy compared to both free EphrinB2 and EVs, as evidenced by the significant upregulation of EphrinB2, VEGF, FGF2, and ANG1 expression at both the translational (Fig. 2G, H) and transcriptional levels (Fig. 2I). While all treatment groups (B2, EVs, and 1-B2-EVs) significantly enhanced angiogenesis relative to controls, the superior therapeutic potency of B2-EVs can be attributed to the synergistic integration of EVs-mediated cargo delivery and EphrinB2-driven signaling. These findings demonstrate that B2-EVs orchestrate vascular regeneration by coordinately modulating critical morphogenic pathways. Importantly, this combinatorial strategy not only amplifies therapeutic outcomes but also reduces dosage requirements, underscoring its translational potential for regenerative medicine applications [48]. Fig. 2B2-EVs promoting migration and angiogenesis of HUVECs in vitro. (A) Representative images of scratch wound healing assay, scale bar: 50 μm; (B) Representative images of Transwell assay, scale bar: 100 μm; (C) Quantitative analysis of scratch closure rate; (D) Quantitative analysis of Transwell cell counts; (E, F) Representative images of tube formation assay (E: Representative images, scale bar: 200 μm; F: Quantitative analysis of branch length and node numbers); (G, H) Western blot analysis of EphrinB2, VEGF, FGF2, and ANG1 protein expression in HUVECs treated with EVs or B2-EVs (GAPDH served as loading control); (I) qRT-PCR analysis of EphrinB2, VEGF, FGF2, and ANG1 mRNA levels in HUVECs. Data represent mean ± SD (n = 3). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant) B2-EVs promoting migration and angiogenesis of HUVECs in vitro. (A) Representative images of scratch wound healing assay, scale bar: 50 μm; (B) Representative images of Transwell assay, scale bar: 100 μm; (C) Quantitative analysis of scratch closure rate; (D) Quantitative analysis of Transwell cell counts; (E, F) Representative images of tube formation assay (E: Representative images, scale bar: 200 μm; F: Quantitative analysis of branch length and node numbers); (G, H) Western blot analysis of EphrinB2, VEGF, FGF2, and ANG1 protein expression in HUVECs treated with EVs or B2-EVs (GAPDH served as loading control); (I) qRT-PCR analysis of EphrinB2, VEGF, FGF2, and ANG1 mRNA levels in HUVECs. Data represent mean ± SD (n = 3). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant) Apt-B2-EVs specifically recognize and target HUVECs Our prior studies established that EVs loaded with EphrinB2 exert potent pro-angiogenic effects essential for tissue regeneration. Nevertheless, the clinical translation of EVs-based therapeutics remains challenging, primarily due to limitations in achieving cell-specific uptake and precise targeting [49]. Aptamers are in vitro-selected ssDNA/RNA oligonucleotides with high-affinity binding capabilities, combining antibody-like targeting with synthetic programmability [25, 50]. Specifically, Apt02 (targeting VEGFR-1/2) mimics VEGF-A’s bioactivity through high-affinity receptor binding and G-quadruplex-enhanced biostability, thereby promoting potent pro-angiogenic effects [30]. Dan Zhao et al. demonstrated that conjugating Apt02 to tFNA significantly amplifies angiogenesis. The tFNA-Apt02 complex enhances endothelial functions in vitro and promotes in vivo vascularization, delivering a nanoengineered therapeutic strategy for tissue vascularization and ischemic diseases [28, 29]. However, the engineering feasibility of Apt-B2-EVs and their targeting specificity require systematic investigation. Capitalizing on the potent VEGF-mimetic bioactivity and enhanced stability of Apt02, we engineered Apt-B2-EVs by covalently conjugating 5’-aldehyde-modified Apt02 to amino groups on the B2-EVs membrane via aldehyde-amine chemistry (Fig. 3A). To verify successful conjugation and functional integrity of Apt-B2-EVs, flow cytometry was performed using Cy5-labeled aptamers with or without aldehyde modification. At a 200 nM concentration, non-aldehyde-modified Apt02 exhibited negligible binding to B2-EVs (Fig. 3D, left panel), whereas aldehyde-modified Apt02 (Apt-CHO) demonstrated robust conjugation efficiency (Fig. 3D, right panel). Quantitative analysis of the conjugation efficiency revealed that approximately 90% of the initial Cy5-Apt02 was successfully conjugated to the EVs, confirming efficient engineering of the Apt-B2-EVs complex. Cell uptake assays revealed that Apt-B2-EVs significantly enhanced the PKH67 signal (indicating vesicle uptake) in HUVECs compared to EVs, B2-EVs, and the random-sequence-modified group (Rd-B2-EVs), all of which exhibited comparable fluorescence (Fig. 3B, C). Co-localization of Cy5-labeled Apt02 (red) with PKH67 further confirmed efficient internalization of Apt-B2-EVs. Parallel Cy5 analysis showed comparable signal intensity between the Apt-B2-EVs and free Apt02 groups, while no Cy5 signal was detected in EVs, B2-EVs, or Rd-B2-EVs. These results demonstrate that Apt02 mediates selective and enhanced cellular uptake of B2-EVs, with specificity attributed to sequence-dependent recognition rather than chemical conjugation artifacts. In co-culture systems with BMSCs. DPSCs, HDPFs and OLCs, immunofluorescence analysis revealed undetectable Cy5 signals (Apt02 tracker) in these stem cells across all control groups (B2-EVs, Rd-B2-EVs) (Fig. S3A-D). Consistent with this specificity, PKH67 intensity (indicating EVs uptake) showed no differences among treatments in BMSCs, DPSCs, HDPFs and OLCs (Fig. S3E-H). This starkly contrasts with our observations in HUVECs, where distinct Cy5 and PKH67 signals were detected exclusively in the Apt-B2-EVs group. Collectively, these findings confirm that Apt02 mediates endothelial-specific EVs internalization without cross-reactivity to mesenchymal stem cells. To elucidate the cellular basis for the enhanced bioactivity, we next assessed the uptake and binding specificity of Apt-B2-EVs in HUVECs under both normal and inflammatory (LPS-stimulated) conditions (Fig. S4A). No statistically significant difference in uptake or binding was observed between the two groups (Fig. S4B). Fig. 3Apt-B2-EVs specifically recognize and target HUVECs. (A) Schematic illustration of covalent conjugation between aldehyde-modified Apt02 and B2-EVs; (B) Fluorescence microscopy of PKH67-labeled EVs (green) internalized by HUVECs, showing enhanced uptake in Apt-B2-EVs versus control groups (EVs, B2-EVs, Apt02, Rd-B2-EVs), scale bar: 200 μm; (C) Quantitative analysis of PKH67 and Cy5 fluorescence intensity in HUVECs; (D) Flow cytometry validation of Apt02 conjugation efficiency: Cy5-labeled aldehyde-free Apt02 (left) versus aldehyde-modified Apt02 (right) binding to B2-EVs. Data represent mean ± SD (n = 3). Significance determined by one-way ANOVA (*p < 0.05; ns: not significant) Apt-B2-EVs specifically recognize and target HUVECs. (A) Schematic illustration of covalent conjugation between aldehyde-modified Apt02 and B2-EVs; (B) Fluorescence microscopy of PKH67-labeled EVs (green) internalized by HUVECs, showing enhanced uptake in Apt-B2-EVs versus control groups (EVs, B2-EVs, Apt02, Rd-B2-EVs), scale bar: 200 μm; (C) Quantitative analysis of PKH67 and Cy5 fluorescence intensity in HUVECs; (D) Flow cytometry validation of Apt02 conjugation efficiency: Cy5-labeled aldehyde-free Apt02 (left) versus aldehyde-modified Apt02 (right) binding to B2-EVs. Data represent mean ± SD (n = 3). Significance determined by one-way ANOVA (*p < 0.05; ns: not significant) Apt-B2-EVs promote angiogenesis and activate the EphrinB2/EphB4-Akt/ERK signaling pathway in HUVECs We assessed whether Apt-B2-EVs enhance pro-angiogenic capacity beyond that of B2-EVs through endothelial-specific homing and sustained EphrinB2 release. In scratch wound healing assays, Apt-B2-EVs exhibited superior endothelial cell migration compared to control groups (EVs, B2-EVs, Apt-EVs), with quantitative analysis revealing a significantly reduced residual wound area at 48 h (Fig. 4A, D). Transwell assays corroborated these findings, showing markedly higher numbers of transmigrated cells in the Apt-B2-EVs group compared to the B2-EVs group (Fig. 4B, E). Tube formation assays further demonstrated that HUVECs treated with Apt-B2-EVs developed more extensive vascular networks, with increased branch complexity and node density compared to controls (Fig. 4C, F). Functional assays revealed that the Apt-EVs group exhibited significantly weaker scratch wound healing, Transwell invasion, and tube formation capacities compared to the Apt-B2-EVs group, indicating that aptamer modification alone is insufficient to achieve full pro-angiogenic activity. Notably, the significantly enhanced bioactivity of Apt-B2-EVs over both B2-EVs and Apt-EVs further underscores a synergistic interplay between sustained EphrinB2 release and Apt02-mediated VEGFR targeting. Molecular analyses revealed that Apt-B2-EVs upregulated the expression of EphrinB2, VEGF, FGF2, and ANG1. Both qRT-PCR and western blot analyses showed consistent trends, with the highest expression levels observed in the Apt-B2-EVs group (Fig. 4G–I). Notably, while Apt-B2-EVs marginally increased EphrinB2 protein levels compared to B2-EVs, EphrinB2 mRNA levels were slightly higher in the B2-EVs group, suggesting possible post-transcriptional regulation. Similarly, VEGF mRNA in the Apt-B2-EVs group showed a nonsignificant upward trend, whereas FGF2 and ANG1 were significantly upregulated. These discrepancies may reflect pathway-specific synergism or biological variability in transcriptional-translational coupling. Collectively, these results indicate that Apt-B2-EVs exert angiogenic efficacy through dual mechanisms: endothelial-specific targeting and sustained EphrinB2 delivery. To further elucidate the pro-angiogenic mechanisms in HUVECs, we investigated how Apt-B2-EVs enhance vascularization. Angiogenesis operates under an integrated signaling network with the Akt, ERK1/2, and EphrinB2/EphB4 pathways serving as pivotal regulatory axes. Critical evidence reveals functional convergence across these pathways, with Ting Zheng et al. demonstrating PI3K/Akt-mediated cerebrovascular protection through suppression of apoptosis and inflammation [51], Wen Ding et al. establishing that dual ERK/Akt blockade inhibits VEGF-driven neovascularization [52], and Weronika Trun et al. proving targeted EphB4-EphrinB2 disruption impairs angiogenesis via receptor dephosphorylation and VEGF/FGF crosstalk inhibition [53]. Significantly, these mechanisms functionally align with our Apt-B2-EVs system, where the VEGFR-1/2 targeting Apt02 aptamer mimics VEGF-A’s proangiogenic activity [30]. This positions Apt-B2-EVs to simultaneously engage Akt-dependent cytoprotection against apoptosis/inflammation, ERK1/2-mediated sprouting potentiation, and EphrinB2/EphB4-VEGFR circuits orchestrating vascular maturation [39, 54, 55]. We therefore hypothesize that Apt-B2-EVs coordinately activate this signaling network to synergistically promote angiogenesis. To test this hypothesis, we subsequently analyzed the expression levels of key proteins within the Akt, ERK1/2, and EphrinB2/EphB4 pathways using WB. As shown in Fig. 4J and K, the phosphorylation levels of Akt and ERK1/2 in the Apt-B2-EVs group were significantly higher than those in the other two groups. Furthermore, the phosphorylation levels of EphrinB2 and EphB4 in both the B2-EVs and Apt-B2-EVs groups were markedly elevated compared to the EVs group. These findings indicate that the targeted delivery capability of Apt02 enhances the release of EphrinB2 onto HUVECs, thereby promoting its interaction with the ligand receptor EphB4. This interaction leads to the phosphorylation of intracellular complex amino acid residues of EphB4, subsequently initiating signaling cascades [42, 53]. It is plausible that the signals transduced by EphrinB2 and EphB4 elicit distinct biological responses in HUVECs, which in turn activate the Akt and ERK1/2 signaling pathways and promote the release of angiogenesis-related factors such as VEGF, ultimately aiding in vascular regeneration. While our study demonstrates the pro-angiogenic effects of Apt-B2-EVs through EphrinB2/EphB4 and VEGF signaling, certain context-dependent mechanisms of EphrinB2 relevant to tissue repair remain unexplored [56–58]. Fig. 4Apt-B2-EVs promote angiogenesis and activate the EphrinB2/EphB4-Akt/ERK signaling pathway in HUVECs. (A) Representative images of scratch wound healing assay, scale bar: 200 μm; (B) Representative images of Transwell assay, scale bar: 100 μm; (C) Quantitative analysis of scratch closure rate; (D) Quantitative analysis of Transwell cell counts; (E) Representative images of tube formation assays, scale bar: 200 μm; (F) Quantitative analysis of vascular network complexity (branch length and node numbers); (G, H) Western blot analysis of EphrinB2, VEGF, FGF2, and ANG1 protein expression in HUVECs treated with Apt-B2-EVs (GAPDH served as loading control); (I) Heatmap visualization of angiogenic gene expression in HUVECs. Relative mRNA levels of EphrinB2, VEGF, FGF2, and ANG1 were quantified by qRT-PCR and normalized to GAPDH. Color scale indicates expression levels, with a gradient from light blue to dark blue representing increasing upregulation; (J) Western blot analysis of phosphorylated Akt (p-Akt), ERK1/2 (p-ERK1/2), EphrinB2/EphB4 (p-EphrinB2/p-EphB4) and their corresponding total protein levels (β-actin served as loading control); (K) Quantitative phospho-signaling activation. * indicates significant differences compared with EVs groups; # indicates significant differences between Apt-B2-EVs and B2-EVs groups. Data represent mean ± SD (n = 3 independent experiments). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). Nonsignificant variation in EphrinB2 (WB) may reflect post-transcriptional regulation or biological variability Apt-B2-EVs promote angiogenesis and activate the EphrinB2/EphB4-Akt/ERK signaling pathway in HUVECs. (A) Representative images of scratch wound healing assay, scale bar: 200 μm; (B) Representative images of Transwell assay, scale bar: 100 μm; (C) Quantitative analysis of scratch closure rate; (D) Quantitative analysis of Transwell cell counts; (E) Representative images of tube formation assays, scale bar: 200 μm; (F) Quantitative analysis of vascular network complexity (branch length and node numbers); (G, H) Western blot analysis of EphrinB2, VEGF, FGF2, and ANG1 protein expression in HUVECs treated with Apt-B2-EVs (GAPDH served as loading control); (I) Heatmap visualization of angiogenic gene expression in HUVECs. Relative mRNA levels of EphrinB2, VEGF, FGF2, and ANG1 were quantified by qRT-PCR and normalized to GAPDH. Color scale indicates expression levels, with a gradient from light blue to dark blue representing increasing upregulation; (J) Western blot analysis of phosphorylated Akt (p-Akt), ERK1/2 (p-ERK1/2), EphrinB2/EphB4 (p-EphrinB2/p-EphB4) and their corresponding total protein levels (β-actin served as loading control); (K) Quantitative phospho-signaling activation. * indicates significant differences compared with EVs groups; # indicates significant differences between Apt-B2-EVs and B2-EVs groups. Data represent mean ± SD (n = 3 independent experiments). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). Nonsignificant variation in EphrinB2 (WB) may reflect post-transcriptional regulation or biological variability Requirement of the EphrinB2/EphB4-Akt/ERK cascade for Apt-B2-EVs-induced angiogenic effects Having established that Apt-B2-EVs activate the EphrinB2/EphB4-Akt/ERK axis, we next sought to determine whether this pathway is causally responsible for the observed pro-angiogenic effects. To delineate the signaling cascade activated by Apt-B2-EVs, HUVECs were treated with EVs, Apt-B2-EVs, Apt-B2-EVs combined with Akt inhibitor (Akti), Apt-B2-EVs combined with ERK inhibitor (ERKi), Apt-B2-EVs combined with NT siRNA, or Apt-B2-EVs combined with EphB4 siRNA. As shown in Fig. 5A and B, EVs alone induced minimal basal levels of all phospho-proteins. In contrast, Apt-B2-EVs markedly upregulated p-EphB4, p-EphrinB2, p-Akt, and p-ERK. Treatment with Akti or ERKi effectively suppressed their respective target phospho-signals (P-Akt or P-ERK), while the levels of p-EphB4 and p-EphrinB2 remained comparable to those in the Apt-B2-EVs alone group, indicating that upstream EphrinB2/EphB4 activation is independent of downstream Akt/ERK signaling. The NT siRNA control group exhibited a phospho-signaling pattern indistinguishable from that of Apt-B2-EVs alone, confirming that the transfection procedure itself did not interfere with pathway activation. Crucially, EphB4 siRNA efficiently silenced EphB4 expression, as evidenced by near-complete loss of total EphB4 protein. Consequently, p-EphB4 and p-EphrinB2 signals were drastically reduced or abolished in the EphB4 siRNA group. Moreover, the elevations in p-Akt and p-ERK observed in the Apt-B2-EVs group were also abrogated upon EphB4 knockdown, with levels reverting to baseline [42]. Collectively, these results position EphrinB2/EphB4 upstream of the Akt and ERK pathways and identify EphB4 as an essential node for Apt-B2-EVs-mediated Akt/ERK activation. We next assessed whether blocking this signaling axis would reverse the functional effects of Apt-B2-EVs. As shown in Fig. 5C-H, Apt-B2-EVs significantly enhanced HUVEC migration and tube formation. Pretreatment with the Akt inhibitor or the ERK inhibitor markedly attenuated these pro-angiogenic effects, although partial activity remained. Strikingly, knockdown of EphB4 completely abrogated the Apt-B2-EVs-induced increases in wound closure, cell invasion and tube formation, reverting them to levels comparable to the EV control group. The NT siRNA control group showed no significant differences from the Apt-B2-EVs alone group in any functional assay, further ruling out non-specific off-target effects. Collectively, these loss-of-function data demonstrate that the EphrinB2/EphB4-Akt/ERK axis is not only activated by but also functionally required for the pro-angiogenic activity of Apt-B2-EVs. These findings indicate that the targeted delivery capability of Apt02 enhances the release of EphrinB2 onto HUVECs, thereby promoting its interaction with the ligand receptor EphB4. This interaction leads to the phosphorylation of intracellular complex amino acid residues of EphB4, subsequently initiating signaling cascades [41, 53]. It is plausible that the signals transduced by EphrinB2 and EphB4 elicit distinct biological responses in HUVECs, which in turn activate the Akt and ERK1/2 signaling pathways and promote the release of angiogenesis-related factors such as VEGF, ultimately aiding in vascular regeneration. While our study demonstrates the pro-angiogenic effects of Apt-B2-EVs through EphrinB2/EphB4 signaling, certain context-dependent mechanisms of EphrinB2 relevant to tissue repair remain unexplored [54, 58]. Fig. 5Requirement of the EphrinB2/EphB4-Akt/ERK cascade for Apt-B2-EVs-induced angiogenic effects. (A) Western blot analysis of phosphorylated Akt (p-Akt), ERK1/2 (p-ERK1/2), EphrinB2 (p-EphrinB2), EphB4 (p-EphB4) and their corresponding total protein levels (β-actin served as loading control); (B) Quantitative phospho-signaling activation. (C) Representative images of scratch wound healing assay at 0 and 48 h post-treatment, scale bar: 100 μm; (D) Representative images of Transwell invasion assay, scale bar: 100 μm; (E) Representative images of tube formation assay on Matrigel, scale bar: 200 μm; (F) Quantitative analysis of wound closure rate at 48 h; (G) Quantitative analysis of invaded cell counts per field at 24 h; (H) Quantitative analysis of tube formation capacity (total branch points and capillary length). Data represent mean ± SD (n = 3 independent experiments). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). * Indicates significant differences compared with the EVs group Requirement of the EphrinB2/EphB4-Akt/ERK cascade for Apt-B2-EVs-induced angiogenic effects. (A) Western blot analysis of phosphorylated Akt (p-Akt), ERK1/2 (p-ERK1/2), EphrinB2 (p-EphrinB2), EphB4 (p-EphB4) and their corresponding total protein levels (β-actin served as loading control); (B) Quantitative phospho-signaling activation. (C) Representative images of scratch wound healing assay at 0 and 48 h post-treatment, scale bar: 100 μm; (D) Representative images of Transwell invasion assay, scale bar: 100 μm; (E) Representative images of tube formation assay on Matrigel, scale bar: 200 μm; (F) Quantitative analysis of wound closure rate at 48 h; (G) Quantitative analysis of invaded cell counts per field at 24 h; (H) Quantitative analysis of tube formation capacity (total branch points and capillary length). Data represent mean ± SD (n = 3 independent experiments). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant). * Indicates significant differences compared with the EVs group Construction and evaluation of Apt-B2-EVs@GelMA-mediated pulp revascularization in organoid models Organoids, defined as self-organizing three-dimensional structures derived from stem cells, offer transformative potential for organ development studies, disease modeling, and therapeutic screening [59–62]. Having previously pioneered zonally organized osteochondral regeneration using phenotype-maintaining GelMA and ion-releasing strontium-substituted xonotlite (Sr-CSH) scaffolds [63, 64], we adopted a similar biomimetic strategy to construct vascularized dental pulp organoids. Specifically, GelMA hydrogel encapsulating HUVECs and Apt-B2-EVs was injected into clinically prepared root canals (Fig. 6A), mimicking both the confined geometry and biochemical milieu of natural tooth pulp. By leveraging GelMA’s tunable viscoelastic properties and the EVs-mediated spatiotemporal delivery of angiogenic factors, these constructs established functional stem cell niches that recapitulated the native vascularized pulp microenvironment [65]. As shown in Fig. 6B and C, after 2 days of co-culture, most of the cells remained viable (green), with only a few dead cells observed (red), and the proportion of viable cells exceeded 90%. This indicates that the EVs, B2-EVs, and Apt-B2-EVs in each extracellular vesicle group exhibited good biocompatibility with GelMA hydrogels. It can therefore be concluded that the addition of extracellular vesicles did not compromise the biocompatibility of GelMA hydrogels. Under co-culture conditions, the release kinetics of EVs, B2-EVs, and Apt-B2-EVs showed nearly identical profiles, with cumulative release exceeding 80% within 10 days (Fig. 6D). These results demonstrate that GelMA hydrogel serves as an effective degradable carrier for the sustained release of Apt-B2-EVs. GelMA and Apt-B2-EVs work synergistically, moving beyond passive scaffold support to actively direct developmental programs, thus offering a developmental engineering paradigm for complex organoid systems. To evaluate the therapeutic efficacy of this delivery system, we next conducted in vivo implantation in a nude mice model of dental pulp revascularization. Fig. 6Construction and evaluation of Apt-B2-EVs@GelMA-mediated pulp revascularization in organoid models. (A) Schematic diagram of the animal experimental design; (B) Live/dead cell staining to assess the biocompatibility of GelMA hydrogel, scale bar: 100 μm; (C) Quantitative analysis of live/dead cell ratio; (D) Release profiles of EVs, B2-EVs, and Apt-B2-EVs from the hydrogel system. Data represent mean ± SD (n = 3) Construction and evaluation of Apt-B2-EVs@GelMA-mediated pulp revascularization in organoid models. (A) Schematic diagram of the animal experimental design; (B) Live/dead cell staining to assess the biocompatibility of GelMA hydrogel, scale bar: 100 μm; (C) Quantitative analysis of live/dead cell ratio; (D) Release profiles of EVs, B2-EVs, and Apt-B2-EVs from the hydrogel system. Data represent mean ± SD (n = 3) Apt-B2-EVs@GelMA promotes pulp revascularization in vivo To evaluate the in vivo pro-angiogenic capacity of GelMA hydrogels encapsulating Apt-B2-EVs@GelMA and their contribution to pulp revascularization, the constructs were implanted under the skin of the back of immunocompromised mice. Key surgical procedures comprised three critical phases: precision subcutaneous pocket creation on the murine dorsum, anatomically positioned implantation, and layered closure technique, all performed under aseptic, minimally invasive protocols (Fig. 7A). After 8 weeks, tooth root segments were harvested, and no adverse events such as rejection, infection, or graft shedding were observed. This confirmed that the ectopic transplantation model possesses good stability and reproducibility [66, 67], making it suitable for in vivo research on pulp revascularization and vascularization mechanisms. Notably, the observed long-term pro-angiogenic effects at 8 weeks, despite the initial burst release, may be attributed to the initiation of a self-sustaining signaling cascade, potential reprogramming of host cells for continuous factor secretion, and the establishment of long-term intercellular communication by the initially delivered EVs. H&E analysis (Fig. 7B) showed differential tissue regeneration among the groups. Blank controls formed disorganized cell clusters without angiogenesis. The B2-EVs@GelMA group generated immature pulp-like tissue with sparse and uneven neovascularization, reflecting partial recovery compared to the B2@GelMA and EVs@GelMA groups. In contrast, the Apt-B2-EVs@GelMA group demonstrated densely organized microvascular networks (with significantly higher density than controls) alongside a connective tissue matrix that resembled native pulp architecture, confirming superior vascularized regeneration. Notably, neovascularization at the dentin interface exhibited centripetal extension toward the root canal centers, suggesting that engineered EVs direct vascular growth through microenvironmental reprogramming. Immunofluorescence analysis (Fig. 7C–E) revealed hierarchical angiogenic responses. The blank control exhibited sparse, discontinuous VEGF signals with no significant positivity. The B2@GelMA and EVs@GelMA groups displayed comparable microvessel density (MVD) and VEGF intensity, confirming baseline pro-angiogenic capacity. The B2-EVs@GelMA group formed partial luminal networks with notable angiogenesis. However, the Apt-B2-EVs@GelMA group demonstrated superior vascularization, exhibiting maximal VEGF intensity, complex branched neovasculature, and lumen integrity that mirrored native pulp microvessels (in contrast to the fragmented tubules seen in the B2-EVs@GelMA group), with significantly higher MVD. This graduated efficacy profile underscores that aptamer-engineered EVs exhibit enhanced targeting specificity towards endothelial-rich niches. The combinatorial modification strategy successfully overcomes biological limitations through synergistic microenvironmental reprogramming, thus providing a pivotal platform for pulp revascularization [68]. Our in vivo findings further demonstrate that the Apt-B2-EVs@GelMA system achieves significant vascularized tissue regeneration over 8 weeks, even though in vitro release kinetics showed a primary burst within 10 days. This apparent discrepancy can be reconciled by considering that the initial bolus of EVs is sufficient to initiate a self-sustaining signaling cascade, potentially reprogram host cells for continuous factor secretion, and establish long-term intercellular communication [69]. It should be noted, however, that this immunodeficient mouse model precludes evaluation of host immune responses. Future studies in immunocompetent models will be essential to fully assess the immunocompatibility and clinical translational potential of this strategy. Furthermore, this study presents additional limitations beyond the use of immunodeficient mice. The experimental duration was relatively short, and the model employed does not fully recapitulate an orthotopic pulp environment, with validation in large-animal models still required. It should be noted that this study primarily focused on addressing the critical challenge of revascularization in pulp regeneration using a well-defined HUVEC model. While this approach effectively demonstrated the pro-angiogenic capacity of our system, it does not fully recapitulate the complex native pulp microenvironment where DPSCs and their derivatives play central roles. Furthermore, important aspects of functional pulp regeneration, including re-innervation and odontogenic differentiation, remain to be investigated. Collectively, these limitations not only delineate the boundaries of our current study but also establish a framework for future investigations into functional pulp regeneration [70–72]. Fig. 7Apt-B2-EVs@GelMA promotes pulp revascularization in vivo. (A) Surgical implantation protocol; (B) H&E staining images of tooth root hydrogel scaffolds, scale bar: 1000 μm; (C) Immunofluorescence staining of VEGF (red) with DAPI nuclear counterstaining (blue), scale bar: 100 μm; (D) Quantification of microvessel density (MVD) based on tubular structures; (E) VEGF immunofluorescence intensity analysis for angiogenic activity. Data represent mean ± SD (n = 3). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant) Apt-B2-EVs@GelMA promotes pulp revascularization in vivo. (A) Surgical implantation protocol; (B) H&E staining images of tooth root hydrogel scaffolds, scale bar: 1000 μm; (C) Immunofluorescence staining of VEGF (red) with DAPI nuclear counterstaining (blue), scale bar: 100 μm; (D) Quantification of microvessel density (MVD) based on tubular structures; (E) VEGF immunofluorescence intensity analysis for angiogenic activity. Data represent mean ± SD (n = 3). Significance determined by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant) Conclusion In summary, we engineered bifunctional extracellular vesicles (Apt-B2-EVs) that effectively orchestrate pulp revascularization by targeting endothelial cell recruitment and regulating angiogenesis. B2-EVs were developed with an optimized EphrinB2 concentration (1 µg/mL), rigorously validated to enhance pro-angiogenic functionality while maintaining membrane integrity. Subsequent functionalization with Apt02 conferred precise endothelial targeting, yielding Apt-B2-EVs that significantly improved in vitro endothelial affinity, promoting endothelial cell proliferation, migration, and tube formation. Mechanistically, Apt-B2-EVs promote angiogenesis via the EphrinB2/EphB4-dependent Akt/ERK signaling cascade. Injection of Apt-B2-EVs@GelMA into clinically prepared root canals established pulp-like organoids with excellent biocompatibility and sustained EVs release. This system markedly enhanced vascularization in vivo, as evidenced by elevated microvascular density and increased VEGF immunofluorescence. In conclusion, Apt-B2-EVs@GelMA represents a promising therapeutic candidate that addresses key challenges in dental pulp revascularization through coordinated ligand-receptor interactions and targeted nanodelivery. This integrated approach provides a conceptual framework for future development of vascularized pulp-like tissue regeneration strategies. Supplementary Information Supplementary Material 1 Supplementary Material 1